Literature DB >> 21642848

Boston type 1 keratoprosthesis combined with silicone oil for treatment of hypotony in prephthisical eyes.

Clara C Chan1, Edward J Holland, William I Sawyer, Kristiana D Neff, Michael R Petersen, Christopher D Riemann.   

Abstract

PURPOSE: To present the outcomes of Boston type I keratoprosthesis (KPro) implantation in combination with pars plana vitrectomy (PPV) and silicone oil for the treatment of hypotony in prephthisical eyes.
METHODS: Interventional case series. Thirteen eyes of 13 patients underwent Boston type I KPro implantation, pars plana vitrectomy, and silicone oil placement. Concurrent retinal detachment repair, membrane peel, or intraocular lens explantation were performed if necessary. Inclusion criteria for surgery were eyes with visual acuity worse than 20/400, previous failed penetrating keratoplasty, corneal opacification, visually significant or worsening hypotony, and visual acuity 20/200 or worse in the fellow eye. Outcome measures included Snellen best-corrected visual acuity, anatomic retinal attachment, and complications.
RESULTS: At the final follow-up (mean, 24 months; range, 5-66 months), visual acuity was improved in 10 of 13 eyes (77%), stable in 2 of 13 eyes (15%), and decreased in 1 of 13 eyes (8%). All eyes had attached retina with no progression to phthisis bulbi. No intraoperative complications occurred. Postoperative complications included retroprosthetic membrane (7 of 13), KPro melt (1 of 13), KPro leak (1 of 13), KPro infection (1 of 13), vitreous hemorrhage (1 of 13), and retinal detachment (1 of 13).
CONCLUSIONS: Boston type I KPro implantation in combination with pars plana vitrectomy and intraocular silicone oil fill can improve vision in most prephthisical eyes with hypotony. Structural findings can also improve.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21642848     DOI: 10.1097/ICO.0b013e318207f3bb

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  6 in total

1.  Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results.

Authors:  Roger A Goldberg; Harry W Flynn; Darlene Miller; Serafin Gonzalez; Ryan F Isom
Journal:  Ophthalmology       Date:  2013-02-28       Impact factor: 12.079

2.  A Large Outbreak of Fulminant Bacterial Endophthalmitis after Intravitreal Injection of Counterfeit Bevacizumab.

Authors:  Morteza Entezari; Saeed Karimi; Hamid Ahmadieh; Amir Hossein Mahmoudi; Hamid Parhizgar; Mehdi Yaseri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-07-04       Impact factor: 3.117

3.  Pars plana vitrectomy through the Boston Keratoprosthesis type 1.

Authors:  M Harissi-Dagher; G M Durr; K Biernacki; M Sebag; M-A Rhéaume
Journal:  Eye (Lond)       Date:  2013-04-12       Impact factor: 3.775

4.  Toward electron-beam sterilization of a pre-assembled Boston keratoprosthesis.

Authors:  Sina Sharifi; Hannah Sharifi; Curtis Guild; Mohammad Mirazul Islam; Khoa D Tran; Corrina Patzer; Claes H Dohlman; Eleftherios I Paschalis; Miguel Gonzalez-Andrades; James Chodosh
Journal:  Ocul Surf       Date:  2021-03-03       Impact factor: 5.033

5.  Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion.

Authors:  Mohamed Abou Shousha; Taher Eleiwa; Allister Gibbons; Christopher Smith; Sean Edelstein; George Kontadakis; Zachary Schmitz; Joshua Abernathy; Ross Chod; Zachary Bodnar; Kelvin McDaniel; Rocio Bentivegna; Levent Akduman
Journal:  J Ophthalmol       Date:  2019-07-25       Impact factor: 1.909

6.  Keratoprosthesis, silicone oil placement, and fluocinolone acetonide implant for treatment of uveitis-associated hypotony and keratopathy.

Authors:  Arman Mosenia; Miel Sundararajan; Jay M Stewart; Julie M Schallhorn
Journal:  J Ophthalmic Inflamm Infect       Date:  2022-02-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.